Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements Of Operations

v2.4.0.6
Consolidated Statements Of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 69 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Operating expenses:      
Research and development $ 4,581 $ 1,246 $ 29,122
General and administrative 2,000 593 9,614
In-process research and development   20,706 20,706
Loss from operations (6,581) (22,545) (59,442)
Interest income 44 19 288
Interest expense (19) (17) (3,302)
Other income     733
Warrant expense     (1,407)
Net loss (6,556) (22,543) (63,130)
Common Stock dividend to Series A Convertible Preferred Stockholders     (5,861)
Net loss attributed to Common Stockholders $ (6,556) $ (22,543) $ (68,991)
Basic and diluted net loss per common share $ (0.35) $ (4.71)  
Weighted average common shares outstanding-basic and diluted 18,604,245 4,791,102